Evidence map›Paper›PMID 37859641›Full record

ArticleInternational journal of cardiology. Heart & vasculature2023

Diagnostic significance of paradoxical left ventricular hypertrophy in detecting cardiac amyloidosis.

Shingo Ota, Yasuhiro Izumiya, Ryoko Kitada, Takahiro Nishi, Akira Taruya, Teruaki Wada, Masahiro Takahata, Yuichi Ozaki, Manabu Kashiwagi, Yasutsugu Shiono and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Recent highlights on myocarditis and cardiomyopathies from theInternational journal of cardiology. Heart & vasculature · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Shingo OtaDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Yasuhiro IzumiyaDepartment of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Ryoko KitadaDepartment of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Takahiro NishiDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Akira TaruyaDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Teruaki WadaDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Masahiro TakahataDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Yuichi OzakiDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Manabu KashiwagiDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Yasutsugu ShionoDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Akio KuroiDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Kazushi TakemotoDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Takashi TanimotoDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Hironori KitabataDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Daiju FukudaDepartment of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Atsushi TanakaDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Wakayama Medical University · JPOsaka Metropolitan University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiac amyloidosis (CA) progresses rapidly with a poor prognosis. Therefore, methods for early diagnosis that are easily accessible in any hospital, are required. We hypothesized that based on the pathology of CA, morphological left ventricular hypertrophy (LVH) without electrical augmentation, namely paradoxical LVH, could be used to diagnose CA. This study aimed to investigate whether paradoxical LVH has diagnostic significance in identifying CA in patients with LVH. Methods: Patients who presented with left ventricular (LV) wall thickness ≥ 12 mm on cardiac magnetic resonance (CMR) were enrolled from a multicentre CMR registry. Paradoxical LVH was defined as a LV wall thickness ≥ 12 mm on CMR, SV1 + RV5 < 3.5 mV, and a lack of secondary ST-T abnormalities. The diagnostic significance of paradoxical LVH in identifying CA was assessed. Results: Of the 110 patients enrolled, 30 (27 %) were diagnosed with CA and 80 (73 %) with a non-CA aetiology. The CA group demonstrated paradoxical LVH more frequently than the non-CA group (80 % vs. 16 %, Conclusions: Paradoxical LVH can be used for identifying CA in patients with LVH. Our findings could contribute to the early diagnosis of CA, even in non-specialized hospitals.

Indexed as

Cardiac amyloidosisCardiovascular magnetic resonance imagingElectrocardiographyLeft ventricular hypertrophy

Identifiers

PMID37859641
PMCPMC10582063
OpenAlexW4387633946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.